Show simple item record

dc.contributor.authorHenry, Ann M
dc.contributor.authorStratford, Julia
dc.contributor.authorMcCarthy, Claire
dc.contributor.authorDavies, Julie
dc.contributor.authorSykes, Jonathan R
dc.contributor.authorAmer, Ali M
dc.contributor.authorMarchant, Thomas E
dc.contributor.authorCowan, Richard A
dc.contributor.authorWylie, James P
dc.contributor.authorLogue, John P
dc.contributor.authorLivsey, Jacqueline E
dc.contributor.authorKhoo, Vincent S
dc.contributor.authorMoore, Christopher J
dc.contributor.authorPrice, Patricia M
dc.date.accessioned2009-07-06T14:47:35Z
dc.date.available2009-07-06T14:47:35Z
dc.date.issued2006-03-15
dc.identifier.citationX-ray volume imaging in bladder radiotherapy verification. 2006, 64 (4):1174-8 Int. J. Radiat. Oncol. Biol. Phys.en
dc.identifier.issn0360-3016
dc.identifier.pmid16376494
dc.identifier.doi10.1016/j.ijrobp.2005.09.044
dc.identifier.urihttp://hdl.handle.net/10541/72591
dc.description.abstractPURPOSE: To assess the clinical utility of X-ray volume imaging (XVI) for verification of bladder radiotherapy and to quantify geometric error in bladder radiotherapy delivery. METHODS AND MATERIALS: Twenty subjects undergoing conformal bladder radiotherapy were recruited. X-ray volume images and electronic portal images (EPIs) were acquired for the first 5 fractions and then once weekly. X-ray volume images were co-registered with the planning computed tomography scan and clinical target volume coverage assessed in three dimensions (3D). Interfraction bladder volume change was described by quantifying changes in bladder volume with time. Bony setup errors were compared from both XVI and EPI. RESULTS: The bladder boundary was clearly visible on coronal XVI views in nearly all images, allowing accurate 3D treatment verification. In 93.5% of imaged fractions, the clinical target volume was within the planning target volume. Most subjects displayed consistent bladder volumes, but 25% displayed changes that could be predicted from the first three XVIs. Bony setup errors were similar whether calculated from XVI or EPI. CONCLUSIONS: Coronal XVI can be used to verify 3D bladder radiotherapy delivery. Image-guided interventions to reduce geographic miss and normal tissue toxicity are feasible with this technology.
dc.language.isoenen
dc.subjectUrinary Bladder Canceren
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshArtifacts
dc.subject.meshCarcinoma, Transitional Cell
dc.subject.meshFemale
dc.subject.meshGases
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMovement
dc.subject.meshProspective Studies
dc.subject.meshRadiotherapy, Conformal
dc.subject.meshTomography, X-Ray Computed
dc.subject.meshUrinary Bladder
dc.subject.meshUrinary Bladder Neoplasms
dc.titleX-ray volume imaging in bladder radiotherapy verification.en
dc.typeArticleen
dc.contributor.departmentAcademic Department of Radiation Oncology, University of Manchester, Manchester, United Kingdom. amhenry@doctors.net.uken
dc.identifier.journalInternational Journal of Radiation Oncology, Biology, Physicsen
html.description.abstractPURPOSE: To assess the clinical utility of X-ray volume imaging (XVI) for verification of bladder radiotherapy and to quantify geometric error in bladder radiotherapy delivery. METHODS AND MATERIALS: Twenty subjects undergoing conformal bladder radiotherapy were recruited. X-ray volume images and electronic portal images (EPIs) were acquired for the first 5 fractions and then once weekly. X-ray volume images were co-registered with the planning computed tomography scan and clinical target volume coverage assessed in three dimensions (3D). Interfraction bladder volume change was described by quantifying changes in bladder volume with time. Bony setup errors were compared from both XVI and EPI. RESULTS: The bladder boundary was clearly visible on coronal XVI views in nearly all images, allowing accurate 3D treatment verification. In 93.5% of imaged fractions, the clinical target volume was within the planning target volume. Most subjects displayed consistent bladder volumes, but 25% displayed changes that could be predicted from the first three XVIs. Bony setup errors were similar whether calculated from XVI or EPI. CONCLUSIONS: Coronal XVI can be used to verify 3D bladder radiotherapy delivery. Image-guided interventions to reduce geographic miss and normal tissue toxicity are feasible with this technology.


Files in this item

This item appears in the following Collection(s)

Show simple item record